// App-Quantinova.ai

152 : Feasibility of docetaxel-prednisone (DP) in frail elderly (age 75 and older) patients with castration-resistant metastatic prostate cancer (CRMPC): GERICO10-GETUG P03 trial led by Unicancer.

Researchers

Presenter

  • Loic Mourey

Principal Investigators

  • Gwenaelle Gravis

  • Emmanuel Sevin

  • Thomas Filleron

  • Frank Priou

  • Emmanuelle Bompas

  • Corinne Sarda

  • Nadine Houede

  • Elisabeth Carola

  • Sophie Abadie Lacourtoisie

  • Igor Latorzeff

  • Christine Orsini

Medical Centers

  • Groupe Hospitalier Public Sud Oise, Senlis, France

  • Clinique Pasteur, Toulouse, France

  • CH Intercommunal Castres, Castres, France

  • Centre Francois Baclesse, Caen, France

  • Institut Bergonie, Bordeaux, France

  • ICO Paul Papin, Angers, France

  • Institut Claudius Regaud, Toulouse, France

  • UNICANCER, Paris, France

  • Centre Rene Gauducheau, Saint-Herblain, France

  • Institut Paoli-Calmettes, Marseille, France

Locations

  • France

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Urology

Disease

  • Prostate cancer

  • Neutropenia

  • Solid malignancies

Biomarkers

  • Circulating tumor cells

Drug/Treatment

  • Prednisone

  • Docetaxel

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • NCT01254513

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved